Summary of Cryomelt medical preparation.

Cryomelt is created by scientists of our company on the basis of the superdense water (Lippincott et al., 1973; Derjaguin B.V. and Churaev N.V., 1973) and the polysaccharide complex isolated from the natural honey.
We produce Cryomelt according to the original patented process and to the Enterprise Pharmaceutical Article FSP 42-0266-1109-01.

Cryomelt passed successfully state clinical tests and has Registration Certificate No. LS-000135 dated 07.06.2010, issued by the Federal Service of Health and Social Development Inspection.
Cryomelt is in the Russian Federation's state register of remedies in concordance with Federal Law No.86-FZ dated 22.06.98.

Cryomelt is an absolutely natural remedy, and does not contain any synthetic substance, has no contra-indications to usage, it combines well with other remedies and does not cause side effects. It is a new generation's drug for liver's treatment which makes possible to restore functioning of liver by complex therapy. The preparation is effective for treatment of acute viral hepatitis, cirrhosis, as well as for liver's antitoxic functioning amelioration.
Experimental research of toxicity and allergenic action testify safety and good tolerance of the product.
Research of adaptogenic activity revealed, that "Taking into consideration natural origin and safety of the product, Cryomelt can be recommended as adaptogen for weak patients and for sports medicine."

Cryomelt's effect.

Cryomelt normalizes level of health and capacity for work. It improves biochemical characteristics, ultrasonic image and ameliorates the quality of life. Treatment with Cryomelt improves noticeably the treatment's expected result and reduces the terms of treatment. Cryomelt has high antiviral activity. Cryomelt normalizes immunity, activates metabolism and organism's cleansing from chemical waste, senescent and tumor cells.
Recent researches revealed that Cryomelt promotes a considerable rejuvenescence of skin, that Cryomelt is capable to increase the cellular viability in human mononuclear blood cells' culture. It may be due to its membrane stabilizing action and to the deterrence of processes, having as result the cellular necrosis, and that it "has the apparent immunomodulatory action, which distinguishes it from others immunotherapy's preparations possessing the antiviral activity".
Clinical study of a medicine Cryomelt was done in Medical centre of the President of Russian Federation (Moscow) and in Medical Academy of the postgraduate formations of Ministry of Health (Sankt - Petersburg) by the instructions of Pharmacological State Committee.
Researches of adaptation activity, allergenic properties and toxicity of a medicine have been executed in Institute of toxicology of the Russian Federation's Ministry of Public Health.